Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

Feb 20 - Eli Lilly (LLY, Financial ... a monoclonal antibody whose drugs are hoped will clear amyloid plaques from the brain in the hope of preventing Alzheimer's onset. Early intervention ...

US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...

This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and ...

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are ... Kisunla is a monoclonal antibody that removes amyloid plaques from the brain, which are associated with the memory-robbing disease.

We're delighted to have with us, again this year, Eli Lilly. Joining us from the Company ... Of course, patients who have amyloid pathology in the brain but no observable symptoms, which is ...

Eli Lilly and Company (NYSE ... people with the mild dementia stage of Alzheimer's disease who have confirmed amyloid pathology.1,2 The Egyptian Drug Authority approved the insulin glargine ...

A so-called 'miracle' Alzheimer's drug caused brain bleeds in more than a third of patients, a new study has revealed.

These are some of the areas where Eli Lilly, flush with cash from its GLP ... Kisunla is a monoclonal antibody that removes amyloid plaques from the brain, which are associated with the memory ...

Eli Lilly says a new starting dose regimen for ... Simply shifting one vial of the anti-amyloid antibody from the first infusion to the third infusion of the titration phase of dosing – the ...

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...